InVivo Therapeutics Shares Resume Trade
$NVIV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
InVivo Therapeutics Shares Resume Trade
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)
4/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)
4 - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)
3 - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)
8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)
8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)
8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)
Study did not achieve primary endpoint of defined improvement on standard impairment scale InVivo to evaluate full data set and strategic options for the company InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI), today announced topline results from the company's INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo's investigational Neuro-Spinal Scaffold™, a bioresorbable scaffold-based device in development for patients with acute SCI. The study did not meet its primary endpoint, which was assessed by the proportion of tre
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has closed its previously announced registered direct offering for the sale and issuance of 154,000 shares of the Company's common stock and pre-funded warrants to purchase up to 369,810 shares of common stock to a single healthcare-focused institutional investor. The Company also closed its previously announced private placement priced at-the-market under Nasdaq rules for the sale and issuance of pre-funded warrants to purchase up to 1,190,476 shares of common stock with the same investor in the
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the Company's common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. Concurrently with the registered direct offering, the Company entered into a definitive agreement with the investor in the registered direct offering for the sale and issuance of 1,190,476 shares of common stock (or
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the appointment of Heather M. Hamel, J.D. as its Chief Legal Officer and General Counsel. In her role, Ms. Hamel will lead the company's legal and intellectual property functions, and provide strategic guidance to the company's Board of Directors and executive management team. Ms. Hamel will also be responsible for the oversight of certain other functions, including business development, human resources and external communications. Prior to this appointment, Ms. Hamel served as the company's Vice Preside
SC 13G/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Subject)
SC 13G/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Subject)
SC 13G/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Subject)